- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 in cholesterol metabolism: from bench to bedside
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 132, Issue 11, Pages 1135-1153
Publisher
Portland Press Ltd.
Online
2018-06-12
DOI
10.1042/cs20180190
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PCSK9 inhibitors in clinical practice: Expectations and reality
- (2018) Željko Reiner ATHEROSCLEROSIS
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
- (2018) Ye-Xuan Cao et al. DIABETES OBESITY & METABOLISM
- PCSK9 inhibition for LDL lowering and beyond – implications for patients with peripheral artery disease
- (2018) Katrin Gebauer et al. Vasa-European Journal of Vascular Medicine
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- Alirocumab for the treatment of hypercholesterolemia
- (2017) Brian Tomlinson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
- (2017) Hua Sun et al. JOURNAL OF LIPID RESEARCH
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
- (2017) Chengfeng Qiu et al. Lipids in Health and Disease
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
- (2017) Usha G. Mallya et al. PHARMACOECONOMICS
- Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
- (2017) Harold E. Bays et al. Journal of the American Heart Association
- PCSK9 signaling pathways and their potential importance in clinical practice
- (2017) Michał Wiciński et al. EPMA Journal
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief ReportHighlights
- (2016) Rutger Verbeek et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Statins and Their Effect on PCSK9—Impact and Clinical Relevance
- (2016) Beth A. Taylor et al. Current Atherosclerosis Reports
- Statins in Stroke Prevention: Present and Future
- (2016) Luis Castilla-Guerra et al. CURRENT PHARMACEUTICAL DESIGN
- Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature
- (2016) Philip Sarges et al. DRUG SAFETY
- Promising new therapies for the treatment of hypercholesterolemia
- (2016) Marcos G. Valerio et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hypothesis
- (2016) Wenguang Wang et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
- (2016) Anne Langsted et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
- (2016) Laura A. Della Badia et al. PHARMACOLOGY & THERAPEUTICS
- Lipoprotein(a) Interactions With Low‐Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)
- (2016) Mehdi Afshar et al. Journal of the American Heart Association
- Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
- (2016) Steve Poirier et al. PLoS One
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness and Population Impact of Statins for Primary Prevention in Adults Aged 75 Years or Older in the United States
- (2015) Michelle C. Odden et al. ANNALS OF INTERNAL MEDICINE
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Epidemiology of Peripheral Artery Disease
- (2015) M. H. Criqui et al. CIRCULATION RESEARCH
- The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity
- (2015) Anastasiya M. Kaneva et al. DISEASE MARKERS
- Alirocumab (Praluent) to Lower LDL-Cholesterol
- (2015) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
- (2015) Terry A. Jacobson et al. Journal of Clinical Lipidology
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profile of evolocumab and its potential in the treatment of hyperlipidemia
- (2015) Arrigo Cicero et al. Drug Design Development and Therapy
- A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
- (2014) Catherine Lunven et al. Cardiovascular Therapeutics
- PCSK9 and LDLR degradation
- (2014) Thomas A. Lagace CURRENT OPINION IN LIPIDOLOGY
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An assessment by the Statin Muscle Safety Task Force: 2014 update
- (2014) Robert S. Rosenson et al. Journal of Clinical Lipidology
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update
- (2013) G.B. John Mancini et al. CANADIAN JOURNAL OF CARDIOLOGY
- AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy
- (2013) Nihar R. Desai et al. CIRCULATION
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
- (2013) Maciej Banach et al. CURRENT PHARMACEUTICAL DESIGN
- Diagnosis and treatment of familial hypercholesterolaemia
- (2013) G. Kees Hovingh et al. EUROPEAN HEART JOURNAL
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
- (2013) et al. EUROPEAN HEART JOURNAL
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
- (2012) Hua Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities
- (2012) K Mahdy Ali et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atomic structure of the autosomal recessive hypercholesterolemia phosphotyrosine-binding domain in complex with the LDL-receptor tail
- (2012) H. Dvir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
- (2011) Fen Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Atherosclerosis: current pathogenesis and therapeutic options
- (2011) Christian Weber et al. NATURE MEDICINE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid Treatment Assessment Project 2
- (2009) David D. Waters et al. CIRCULATION
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
- (2009) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
- (2009) Markey C. McNutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
- (2009) S. A. Mousavi et al. JOURNAL OF INTERNAL MEDICINE
- Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells
- (2008) Tommaso Fasano et al. ATHEROSCLEROSIS
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population
- (2007) Pia R. Kamstrup et al. CIRCULATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search